Product development, including medical equipment and rehabilitation equipment, driven by customer challenges
First written in FY2016. 25 of 26 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「The main research and development activities during the consolidated fiscal year were the development of high-function medical equipment, rehabilitation equipment and special bathtubs focused on ease of use and safety in the Total Pack Produce business. Research and development expenses amounted to ¥425 million. In the Medical Supply business, research and development expenses related to the development of the Company's own orthopedic products amounted to ¥35 million.」
Research and development of medical equipment, rehabilitation equipment and other products based on challenges faced in medical settings continued, and total research and development expenses amounted to ¥460 million. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥229 million. There were no material changes in the group's R&D activities during the interim consolidated accounting period.」
The absence of material changes in R&D activities based on customer needs was reconfirmed, and R&D expenses were ¥229 million. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥215 million. There were no material changes in the group's R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥215 million were recorded, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥292 million. There were no material changes in the group's R&D activities during the cumulative third quarter.」
R&D expenses of ¥292 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥201 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses of ¥201 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥81 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses of ¥81 million were recorded, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥174 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses of ¥174 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥77 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses of ¥77 million were recorded, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2022RestatedAnnual report
「Our group actively develops products by continually identifying and addressing customer needs. To this end, it gathers information on issues from medical sites, which are the users, and develops products to address them.」
The policy of developing products based on issues identified at medical sites continued. R&D expenses were ¥399 million for the Total Pack Produce business and ¥28 million for the Medical Supply business. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥169 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses of ¥169 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥92 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses of ¥92 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2021RestatedAnnual report
「Our group actively develops products by continually identifying and addressing customer needs. To this end, it gathers information on issues from medical sites, which are the users, and develops products to address them.」
The policy of developing products based on issues identified at medical sites continued, with R&D expenses of ¥318 million for medical equipment and other products and ¥42 million for orthopedic products. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥240 million. There were no material changes in the group's R&D activities during the cumulative third quarter.」
R&D expenses of ¥240 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥160 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses of ¥160 million were recorded, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥74 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses of ¥74 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2020RestatedAnnual report
「The group's main R&D activities during the consolidated fiscal year consisted of developing advanced medical equipment, rehabilitation equipment and special bathtubs in the Total Pack Produce business, with a focus on ease of use and safety. R&D expenses for these activities were ¥307 million. R&D expenses for the development of in-house orthopedic products in the Medical Supply business were ¥34 million.」
Product development based on issues identified at medical sites continued, with R&D expenses of ¥307 million for medical equipment and rehabilitation equipment and ¥34 million for in-house orthopedic products. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥240 million. There were no material changes in the group's R&D activities during the cumulative third quarter.」
R&D expenses of ¥240 million were recorded, reconfirming that there were no material changes in R&D activities. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥156 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses of ¥156 million were recorded, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥68 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses were ¥68 million, reconfirming that there were no material changes in R&D activities based on customer needs. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥154 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses were ¥154 million, reconfirming that there were no material changes in R&D activities. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥69 million. There were no material changes in the group's R&D activities during the cumulative first quarter.」
R&D expenses were ¥69 million, reconfirming that there were no material changes in R&D activities. - FY2018RestatedAnnual report
「Our group actively develops products by continually identifying and addressing customer needs. To this end, it gathers information on issues from medical sites, which are the users, and develops products to address them.」
Product development based on issues identified at medical sites continued, and R&D expenses for the period were ¥350 million. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥253 million. There were no material changes in the group's R&D activities during the cumulative third quarter.」
R&D expenses were ¥253 million, reconfirming that there were no material changes in R&D activities. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥171 million. There were no material changes in the group's R&D activities during the cumulative second quarter.」
R&D expenses were ¥171 million, reconfirming that there were no material changes in R&D activities. - FY2017-Q3RestatedAnnual report
「There were no material changes in the Group's R&D activities during the cumulative third quarter of the fiscal year.」
It is explicitly stated that there were no material changes in R&D activities, confirming the continuation of product development based on customer needs. - FY2016First statedAnnual report
「Our group actively develops products by continually identifying and addressing customer needs.」
The company gathers information on issues from medical sites and develops advanced medical equipment, rehabilitation equipment, special bathtubs and other products. R&D expenses for the period were ¥456 million.